Also trades as: ESLAW (NASDAQ) · $vol 0M
ESLA NASDAQ
Estrella Immunopharma, Inc.
1W: -5.8%
1M: -37.0%
3M: -8.8%
YTD: -18.0%
1Y: +18.9%
3Y: -89.5%
$1.14
+0.02 (+1.79%)
Weekly Expected Move ±11.4%
$1
$1
$1
$1
$1
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Smart Money Score
Moderate
50
Insider—
Congress—
ETF Holdings—
Key Statistics
Market Cap$48.6M
52W Range0.78-3.15
Volume25,016
Avg Volume87,270
Beta0.98
Dividend—
Analyst Ratings
Company Info
CEOCheng Liu
Employees3
SectorHealthcare
IndustryBiotechnology
IPO Date2021-09-14
Websiteestrellabio.com
5858 Horton Street
EmeryVille, CA 94608
US
EmeryVille, CA 94608
US
510 318 9098
About Estrella Immunopharma, Inc.
Estrella Immunopharma, Inc., a preclinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidates include EB103 for the treatment of diffuse large B-cell lymphoma and is in pre clinical trial; and EB104 to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia. It has a collaborative partnership with Imugene Limited for the development of solid tumor treatments using Imugene's product candidate CF33-CD19t in conjunction with EB103. Estrella Immunopharma, Inc. is based in EmeryVille, California.
Latest News
12 Health Care Stocks Moving In Friday's After-Market Session
12 Health Care Stocks Moving In Tuesday's Intraday Session
12 Health Care Stocks Moving In Monday's Intraday Session
12 Health Care Stocks Moving In Tuesday's After-Market Session
Estrella Immunopharma Presents Promising Updated Data on EB103 in Oral Presentation at the 2026 Tandem Meetings of ASTCT® & CIBMTR®
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Xu Jiandong | P-Purchase | 1,000 | $1.33 | 2025-10-07 |
| Xu Jiandong | P-Purchase | 1,000 | $1.16 | 2025-09-22 |
| Jia Dengyao | 0 | — | 2025-09-22 | |
| Xu Jiandong | P-Purchase | 100 | $1.04 | 2025-09-11 |
| Liu Cheng | A-Award | 509,204 | $0.81 | 2024-10-30 |